September's most consequential personal care story was a potential consolidation at the top of the ingredients supply chain: BASF has signaled interest in Evonik, a move that would redraw the specialty chemicals map formulators and procurement teams work from.

Personal Care Insights' month-in-review also flagged two other threads that demand attention from industry professionals: the EU Green Transition Directive, which adds another compliance layer for anyone selling into Europe, and the accelerating conversation around GLP-1 drugs and their spillover into beauty demand.

Why does BASF's interest in Evonik matter?

Both companies sit among the largest suppliers of actives, emollients, surfactants and functional ingredients to global cosmetic manufacturers. Any combination would concentrate significant INCI-grade supply under one roof.

For buyers, the immediate questions are practical:

• Will overlapping product lines be divested, and which INCI names could change hands or disappear from price lists?
• How will dual-sourcing strategies hold up if two independent suppliers become one?
• What leverage will brands have in annual negotiations with a larger counterparty?

For formulators, portfolio rationalization is the standard follow-on to any merger of this kind. Reformulation risk tends to surface quietly, when a legacy grade is discontinued or a technical data sheet is revised. Teams that map their bills of materials now, ingredient by ingredient, will be better positioned than those that wait for the first discontinuation notices.

Deals of this scale also draw antitrust scrutiny in the EU and the US, which means any actual transaction would likely take quarters, not weeks, to close. The watch item is whether formal talks are confirmed and which regulatory bodies open files.

What does the Green Transition Directive change?

The EU Green Transition Directive continues the bloc's push against greenwashing and vague environmental claims in consumer-facing communication — territory cosmetics brands enter every time they market a product as "clean," "natural" or climate-friendly.

The compliance workload lands hardest on marketing and regulatory teams at brands selling into the EU:

• Substantiation files for environmental claims will need to withstand a higher evidentiary bar.
• Generic environmental claims without recognized performance may become legally risky rather than merely reputational so.
• Review cycles for packaging copy, web content and influencer briefs will need legal sign-off earlier in the process.

Suppliers should expect brands to push substantiation requests down the value chain — requesting lifecycle data, certificates and carbon footprints at the ingredient level, not just safety documentation.

The practical next step for affected companies is a claims audit: inventory every environmental statement currently in market, map each to its evidence, and flag the gaps before enforcement priorities are published.

Is GLP-1 reshaping beauty demand?

The third strand of September's coverage — GLP-1 drugs and beauty — tracks the consumer story of the year. As weight-loss medications scale into mass use, adjacent categories are reporting visible effects on treatment menus and product briefs.

The areas most directly touched:

• Skin: reported demand for firming and elasticity claims as users confront facial volume loss, often branded "Ozempic face" in consumer media.
• Body care: contouring and skin-condition claims tied to rapid body composition change.
• Professional treatments: clinics adjusting menus toward skin boosters, biostimulators and lifting protocols for this patient profile.

For product development teams, the opportunity is claim-specific formulation — actives and delivery systems targeted at laxity and barrier stress rather than generic anti-aging language. For spa and clinic operators, GLP-1 users represent a distinct client segment with distinct protocols and consultation scripts.

The data point to watch here is any peer-reviewed or supplier-published study quantifying skin changes in GLP-1 populations — that would convert anecdote into formulation targets and give the first movers a defensible claims basis.

What ties the month together?

September's three stories converge on one theme: the personal care value chain is being repriced — by consolidation upstream at BASF and Evonik, by regulation in Brussels, and by pharmacology in the consumer base. Each moves at a different speed. The M&A story could break open or stall within a quarter; the directive's enforcement timetable will define compliance budgets for 2025–2026; GLP-1 demand data will keep arriving quarter by quarter.

Professional readers should track all three calendars: antitrust filings in Germany and Brussels, EU implementing texts on environmental claims, and the first clinical datasets on GLP-1 and skin.